Education
About Us
Working with TipRanks
Follow Us
VolitionRX Ltd. (VNRX)
:VNRX
VNRX Stock Chart & Stats
$0.45
$0.01(1.52%)
At close: 4:00 PM EST
$0.45
$0.01(1.52%)
Day’s Range― - ―
52-Week Range$0.33 - $0.94
Previous CloseN/A
Volume29.92K
Average Volume (3M)995.63K
Market Cap
$40.66M
Enterprise Value$83.20M
Total Cash (Recent Filing)$199.41K
Total Debt (Recent Filing)$1.91M
Price to Earnings (P/E)―
Beta0.46
Next Earnings
Mar 31, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding122,801,575
10 Day Avg. Volume825,693
30 Day Avg. Volume995,625
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-2.08
Price to Sales (P/S)42.09
P/FCF Ratio-1.96
Enterprise Value/Market Cap2.05
Enterprise Value/Revenue56.52
Enterprise Value/Gross Profit98.49
Enterprise Value/Ebitda-5.19
Forecast
1Y Price Target
$2.50Price Target Upside455.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market ExpansionVolitionRx plans to expand the Nu.Q Vet business with completion of the feline lymphoma testing application, which would trigger a $5 million milestone payment.
Revenue GrowthPotential upfront and milestone payments, as well as future recurring royalties from agreements, are expected to drive Volition’s topline growth.
Strategic PartnershipsVolitionRx has entered an agreement with Hologic Diagenode for the co-marketing of Volition’s Nu.Q Discover service, aiming to expand its customer base.
Bears Say
Development RisksRisks include failure in clinical development of diagnostic products, failure to secure license agreements, failure to achieve market traction, dilution risk, and going concern risk and delisting risk.
Financial RisksThe company may need to raise additional capital in the near term if sufficient cash is not received from the upcoming licensing deal.
VolitionRX News
VNRX FAQ
What was VolitionRX Ltd.’s price range in the past 12 months?
VolitionRX Ltd. lowest stock price was $0.33 and its highest was $0.94 in the past 12 months.
What is VolitionRX Ltd.’s market cap?
VolitionRX Ltd.’s market cap is $40.66M.
When is VolitionRX Ltd.’s upcoming earnings report date?
VolitionRX Ltd.’s upcoming earnings report date is Mar 31, 2026 which is in 133 days.
How were VolitionRX Ltd.’s earnings last quarter?
VolitionRX Ltd. released its earnings results on Nov 13, 2025. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of -$0.044 by -$0.006.
Is VolitionRX Ltd. overvalued?
According to Wall Street analysts VolitionRX Ltd.’s price is currently Undervalued.
Does VolitionRX Ltd. pay dividends?
VolitionRX Ltd. does not currently pay dividends.
What is VolitionRX Ltd.’s EPS estimate?
VolitionRX Ltd.’s EPS estimate is -0.05.
How many shares outstanding does VolitionRX Ltd. have?
VolitionRX Ltd. has 122,801,575 shares outstanding.
What happened to VolitionRX Ltd.’s price movement after its last earnings report?
VolitionRX Ltd. reported an EPS of -$0.05 in its last earnings report, missing expectations of -$0.044. Following the earnings report the stock price went down -5.714%.
Which hedge fund is a major shareholder of VolitionRX Ltd.?
Currently, no hedge funds are holding shares in VNRX
VolitionRX Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.50 (455.56% Upside)
$2.50 (455.56% Upside)
Blogger Sentiment
Bullish
VNRX Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $239.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.02%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-49.14%
Trailing 12-Months
Company Description
VolitionRX Ltd.
VolitionRx Limited (VNRX) is a biotechnology company focused on developing blood-based diagnostic tests for cancer detection and monitoring. The company operates primarily in the healthcare sector, utilizing its proprietary Nucleosomics™ technology to identify cancer-related biomarkers in the blood. VolitionRx aims to provide accurate, easy-to-use, and cost-effective diagnostic solutions that can improve patient outcomes through early detection and monitoring of cancer.
VNRX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in revenue growth, cost management, and strategic partnerships with major companies like Werfen and Hologic. Scientific advancements also promise future potential. However, challenges remain, such as unpredictable revenue and uncertainty in closing additional licensing agreements.View all VNRX earnings summariesVNRX Stock 12 Month Forecast
Average Price Target
$2.50
▲(455.56% Upside)
Technical Analysis
Ownership Overview
10.71% Insiders
1.92% Mutual Funds
10.72% Other Institutional Investors
75.80% Public Companies and
Individual Investors